thalidomide has been researched along with Herpes Zoster in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Herpes Zoster: An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The incidence of herpes zoster is substantial during bortezomib treatment in patients with multiple myeloma (MM)." | 7.81 | Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy. ( Choe, PG; Kim, BS; Kim, I; Kim, JW; Koh, Y; Kwon, JH; Min, CK; Mun, YC; Nam, SH; Park, WB; Park, Y, 2015) |
| " We present a case of coinfection with disseminated HSV and VZV infection in a patient taking thalidomide for relapsed multiple myeloma." | 7.71 | Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma. ( Curley, MJ; Hassoun, PM; Hussein, SA, 2002) |
| "The incidence of herpes zoster is substantial during bortezomib treatment in patients with multiple myeloma (MM)." | 3.81 | Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy. ( Choe, PG; Kim, BS; Kim, I; Kim, JW; Koh, Y; Kwon, JH; Min, CK; Mun, YC; Nam, SH; Park, WB; Park, Y, 2015) |
| " We present a case of coinfection with disseminated HSV and VZV infection in a patient taking thalidomide for relapsed multiple myeloma." | 3.71 | Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma. ( Curley, MJ; Hassoun, PM; Hussein, SA, 2002) |
| " Thalidomide (Synovir), developed by Celgene, has received limited approval for the treatment of leprosy." | 3.70 | FDA approves fomivirsen, famciclovir, and Thalidomide. Food and Drug Administration. ( Highleyman, L, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| König, C | 1 |
| Kleber, M | 1 |
| Reinhardt, H | 1 |
| Knop, S | 1 |
| Wäsch, R | 1 |
| Engelhardt, M | 1 |
| Kim, JW | 1 |
| Min, CK | 1 |
| Mun, YC | 1 |
| Park, Y | 1 |
| Kim, BS | 1 |
| Nam, SH | 1 |
| Koh, Y | 1 |
| Kwon, JH | 1 |
| Choe, PG | 1 |
| Park, WB | 1 |
| Kim, I | 1 |
| Highleyman, L | 1 |
| Curley, MJ | 1 |
| Hussein, SA | 1 |
| Hassoun, PM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Immune Response Induced by Zoster Vaccine According to the Timing of Vaccination After Zoster Illness[NCT02704572] | 60 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| Comparison of Change in Humoral and Cellular Immunity Induced by Zoster Vaccine According to the Timing of Vaccination After Hematopoietic Stem Cell Transplantation[NCT03192319] | 86 participants (Actual) | Interventional | 2017-07-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for thalidomide and Herpes Zoster
| Article | Year |
|---|---|
Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients.
Topics: Acyclovir; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibiotic Prophylaxis; Antiviral Agent | 2014 |
Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Female; Herpes Zoster; Herpesviru | 2015 |
Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Female; Herpes Zoster; Herpesviru | 2015 |
Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Female; Herpes Zoster; Herpesviru | 2015 |
Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Female; Herpes Zoster; Herpesviru | 2015 |
FDA approves fomivirsen, famciclovir, and Thalidomide. Food and Drug Administration.
Topics: 2-Aminopurine; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; D | 1998 |
Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma.
Topics: Angiogenesis Inhibitors; Female; Herpes Simplex; Herpes Zoster; Humans; Middle Aged; Multiple Myelom | 2002 |